A5028647941- Antibiotic Resistance in Bacteria
- Bacterial Identification and Susceptibility Testing
- Antibiotic Use and Resistance
- Antibiotics Pharmacokinetics and Efficacy
- Pharmaceutical and Antibiotic Environmental Impacts
- SARS-CoV-2 detection and testing
- Vibrio bacteria research studies
- Enterobacteriaceae and Cronobacter Research
- Viral gastroenteritis research and epidemiology
- Infections and bacterial resistance
- Salmonella and Campylobacter epidemiology
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Clostridium difficile and Clostridium perfringens research
- Dental Research and COVID-19
- Genomics and Phylogenetic Studies
- Escherichia coli research studies
- Biosensors and Analytical Detection
- COVID-19 and healthcare impacts
- Hepatitis Viruses Studies and Epidemiology
- Urinary Tract Infections Management
- Bacterial biofilms and quorum sensing
- Cystic Fibrosis Research Advances
- Cancer Research and Treatments
- Bacteriophages and microbial interactions
National Center for Emerging and Zoonotic Infectious Diseases
2020-2024
Centers for Disease Control and Prevention
2018-2024
Utah Department of Health
2021
Texas Department of State Health Services
2021
Arkansas Department of Health
2021
Virginia Department of Health
2021
Secretaria de Salud
2021
United States Department of Health and Human Services
2021
Washington State Department of Health
2021
Arizona Department of Health Services
2021
To address high COVID-19 burden in U.S. nursing homes, rapid SARS-CoV-2 antigen tests have been widely distributed those facilities. However, performance data are lacking, especially asymptomatic people.
Carbapenemase gene-positive (CP) Gram-negative bacilli are of significant clinical and public health concern. Their rapid detection containment critical to preventing their spread additional infections they can cause.
The treatment of infections caused by carbapenem-resistant Enterobacterales , especially New Delhi metallo-β-lactamase (NDM)-producing bacteria, is challenging. Although less common in the United States than some other carbapenemase producers, NDM-producing bacteria are a public health threat due to limited options available. Here, we report on antibiotic susceptibility 275 contemporary collected from 30 U.
is a Gram-negative bacillus that can cause severe and difficult-to-treat healthcare-associated infections.
Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing Enterobacterales combining ceftazidime-avibactam aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing broth microdilution. For 64 isolates tested, the MIC50 MIC90 values were 0.5/4 μg/ml 8/4 μg/ml, respectively. displayed potent...
Aztreonam-avibactam is a combination antimicrobial agent with activity against carbapenemase-producing Enterobacteriaceae (CPE) metallo-β-lactamases (MβLs). Although aztreonam-avibactam not yet approved by the U.S. Food and Drug Administration (FDA), clinicians can administer this using two FDA-approved drugs: aztreonam ceftazidime-avibactam. This of drugs recommended multiple experts for treatment serious infections caused MβL-producing CPE. At present, in vitro susceptibility testing (AST)...
Aztreonam/avibactam is a combination agent that shows promise in treating infections caused by highly antibiotic-resistant MBL-producing Enterobacterales. This can be achieved combining two FDA-approved drugs: ceftazidime/avibactam and aztreonam. It unknown whether ceftazidime the ceftazidime/aztreonam/avibactam has synergistic or antagonistic effect on vitro activity of aztreonam/avibactam significantly increasing decreasing MIC.
Detection of carbapenem-resistant Pseudomonas aeruginosa (CRPA) with carbapenemase-producing (CP) genes is critical for preventing transmission. Our objective was to assess whether certain antimicrobial susceptibility testing (AST) profiles can efficiently identify CP-CRPA. We defined CRPA as P. imipenem or meropenem MICs ≥8 μg/ml; CP-CRPA CP (blaKPC/blaIMP/blaNDM/blaOXA-48/blaVIM). assessed the sensitivity and specificity AST detect among isolates collected by CDC's Antibiotic Resistance...
Abstract Background To estimate the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in older adults with underlying conditions, we assessed duration disease 2019 (COVID-19) symptoms, reverse-transcription polymerase chain reaction (RT-PCR) positivity, and culture positivity among nursing home residents. Methods We enrolled residents within 15 days their first positive SARS-CoV-2 test (diagnosis) at an Arkansas facility from July 7 to 15, 2020 instead them...
Our objectives were to identify Shigella isolates in the United States with decreased susceptibility azithromycin (DSA) and characterize genetic mechanisms responsible for this resistance.
Typhoid fever in the United States is acquired primarily through international travel by unvaccinated travelers. There currently no typhoid vaccine licensed for use children <2 years.We reviewed Salmonella enterica serotype Typhi infections reported to Centers Disease Control and Prevention (CDC) antimicrobial-resistance data on isolates CDC's National Antimicrobial Resistance Monitoring System from 1999 2015.5131 cases of were diagnosed 5004 tested antimicrobial susceptibility. Among 1992...
Abstract Background Historically, United States’ carbapenem-resistant Enterobacterales (CRE) surveillance and mechanism testing focused on three genera: Escherichia, Klebsiella, Enterobacter (EsKE); however, other genera can harbour mobile carbapenemases associated with CRE spread. Objectives From January through May 2018, we conducted a 10 state evaluation to assess the contribution of less common (LCG) carbapenemase-producing (CP) CRE. Methods State public health laboratories (SPHLs)...
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing remains essential for early identification and clinical management of cases. We compared the diagnostic performance 3 specimen types characterizing SARS-CoV-2 in infected nursing home residents. Methods A convenience sample 17 residents were enrolled within 15 days first positive result by real-time reverse transcription polymerase chain reaction (RT-PCR) prospectively followed 42 days. Anterior nasal...
ABSTRACT Carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are significant public health threats, particularly when harboring carbapenemases. Literature describing the frequencies phenotypic genotypic characteristics of isolates multiple carbapenemase genes is limited. Using data collected from Antimicrobial Resistance Laboratory Network (AR Lab Network) in 2018–2022, we describe CRE CRPA that harbor acquired genes. Clinical laboratories...
Abstract Background Infections with metallo-β-lactamase (MBL)-producing organisms are emerging in the United States. Treatment options for these infections limited. We describe MBL genes among carbapenemase positive carbapenem-resistant Enterobacteriaceae (CP-CRE) and Pseudomonas aeruginosa (CP-CRPA) isolates tested during first two years of Antibiotic Resistance Laboratory Network (AR Lab Network). Methods State local public health laboratories CRE CRPA organism identification,...
In 2017, the Centers for Disease Control and Prevention (CDC) established Antimicrobial Resistance Laboratory Network to improve domestic detection of multidrug-resistant organisms. CDC four laboratories evaluated a commercial broth microdilution panel. susceptibility testing using Sensititre GN7F (ThermoFisher Scientific, Lenexa, KS) was by 100 Food Drug Administration AR Isolate Bank isolates [40 Enterobacterales (ENT), 30
Background: Carbapenem-resistant Enterobacteriaceae (CRE) cause significant morbidity and mortality each year in the United States. Treatment options for these infections are often limited, part due to carbapenemases, which mobile β-lactam-hydrolyzing enzymes that confer multidrug resistance CRE. As of CDC’s Containment Strategy Emerging Resistance, public health laboratories (PHLs) CDC Antibiotic Resistance Laboratory Network (AR Lab Network) have worked characterize clinical isolates CRE...
Abstract Background In the United States, typhoid fever is rare. About 300 cases are reported to CDC annually through National Typhoid and Paratyphoid Fever Surveillance (NTPFS) system. Most acquired during international travel while visiting friends relatives. recommends pretravel vaccination of at-risk children with one two currently available vaccines: oral (age ≥6 years) or injectable ≥2 years). anticipation licensure new protein-conjugate vaccines that could be administered months old,...
Abstract Background Metallo-β-lactamase-producing Enterobacterales (MBL-E) are a major public health concern as they cause infections with few effective treatment options. Aztreonam-avibactam (AZA) is β-lactam/β-lactamase inhibitor combination agent in the drug development pipeline that active against MBL-E. Though clinical studies ongoing, components can be administered by combining two FDA-approved drugs: aztreonam and ceftazidime-avibactam. In 2019, CDC initiated program Antimicrobial...
Abstract Background The recent discovery of carbapenemase-producing hypervirulent Klebsiella pneumoniae (CP-HvKP) has signaled the convergence multidrug resistance and pathogenicity, with potential for increased mortality. While previous studies CP-HvKP isolates revealed that most carried carbapenemase genes hypervirulence elements on separate plasmids, a 2018 report from China confirmed both could be harbored single, hybrid carbapenemase-hypervirulent plasmid. As part project sequencing...
Background: Carbapenemase-producing Enterobacteriaceae (CPE) are a major public health concern because they typically display multidrug resistance and cause hard-to-treat infections. Organisms harboring metallo-β-lactamases (MBLs) pose critical challenge in clinical practice confer to nearly all β-lactams, including recently approved β-lactam combination agents. A promising new β - lactam lactamase inhibitor for treating infections caused by MBL-producing CPE is aztreonam–avibactam. Although...
Background: In the United States, carbapenemases are rarely cause of carbapenem resistance in Pseudomonas aeruginosa. Detection carbapenemase production (CP) carbapenem-resistant P. aeruginosa (CRPA) is critical for preventing its spread, but testing many isolates required to detect a single CP-CRPA. The CDC evaluates CRPA CP through (1) Antibiotic Resistance Laboratory Network (ARLN), which submitted from participating clinical laboratories public health and antimicrobial susceptibility...